Plagiarism Policy
Pharma Studies Policies · Research Integrity
Publication Ethics | COPE Guidelines
International Journal of Pharma Studies
The International Journal of Pharma Studies considers originality, scientific integrity, and proper attribution essential to responsible pharmaceutical and scholarly publishing. Authors are expected to ensure that submitted manuscripts are original and that words, ideas, research data, experimental results, figures, tables, chemical structures, and other material obtained from other sources are appropriately acknowledged.
Originality and Proper Attribution
Manuscripts submitted to the International Journal of Pharma Studies should not present material originating from another source as the author's own. Authors must provide appropriate citations and acknowledgments for material used from published or publicly available sources.
Plagiarism may include, but is not limited to:
Copying or closely reproducing text without appropriate attribution.
Presenting another person's ideas, findings, pharmaceutical research, or intellectual work as one's own.
Using figures, tables, experimental data, chemical structures, molecular models, images, or other third-party material without appropriate acknowledgment or permission where required.
Presenting another researcher's drug development findings, clinical trial results, laboratory observations, or scientific interpretations as original work.
Reusing substantial material from an author's own previously published work without appropriate acknowledgment where this creates a misleading impression of originality.
Authors are responsible for ensuring that all sources are properly acknowledged and that the manuscript does not contain unattributed or misleadingly presented material.
Similarity Screening
The International Journal of Pharma Studies may screen submitted manuscripts using appropriate similarity-detection or plagiarism-screening tools as part of the editorial assessment process.
A similarity result does not by itself establish plagiarism. Identified matches may arise from legitimate quotations, references, commonly used pharmaceutical terminology, standard laboratory procedures, descriptions of established analytical methods, or other acceptable sources. The editorial team may consider the nature, extent, context, and source of identified similarities before determining whether further action is appropriate.
The journal does not treat a particular similarity percentage as an automatic determination of plagiarism.
Duplicate and Redundant Publication
Authors must not submit the same or substantially similar manuscript simultaneously to multiple journals.
Previously published research or substantial portions of previously published material must be appropriately disclosed and cited. Authors should avoid redundant publication or text recycling that could create a misleading impression of new or original pharmaceutical research.
Where a manuscript is based on or substantially overlaps with a previously published study, clinical investigation, drug evaluation, or experimental research project, authors should clearly explain the relationship between the works and identify any reused data or material.
Preprints and Previously Shared Material
Prior posting of a manuscript as a preprint does not automatically constitute plagiarism. Authors should disclose relevant preprint information during submission and appropriately identify and cite the preprint where applicable.
Authors remain responsible for ensuring that submitted manuscripts meet the journal's requirements concerning originality, attribution, copyright, and publication history, including the appropriate disclosure of previously shared pharmaceutical research findings.
Third-Party Material
Authors are responsible for obtaining appropriate permission where required for the use or reproduction of copyrighted figures, tables, images, chemical structures, molecular diagrams, substantial text, or other third-party material.
Such material must be properly attributed, and applicable licensing or permission requirements must be followed. Authors should also ensure that any reproduced clinical, laboratory, or pharmaceutical research material complies with relevant confidentiality and data protection requirements.
Plagiarism Identified During Review
If substantial unattributed material or suspected plagiarism is identified before publication, the International Journal of Pharma Studies may request an explanation or supporting information from the authors.
Depending on the circumstances and available evidence, the manuscript may require clarification, may be rejected, or may be referred for further editorial assessment. Where necessary, concerns involving research data, experimental findings, clinical trial results, or scientific misconduct may be examined under the journal's applicable editorial and publication ethics procedures.
Plagiarism Identified After Publication
If credible concerns regarding plagiarism or substantial unattributed material arise after publication, the International Journal of Pharma Studies may investigate the matter and take appropriate action based on the available evidence.
Possible editorial actions may include correction, withdrawal where applicable, retraction, or another appropriate editorial measure. Such actions will be considered in accordance with the journal's relevant policies and procedures, taking into account the nature and seriousness of the concern.
This policy is informed by relevant guidance from the Committee on Publication Ethics (COPE), where applicable.